Abstract
CD147, a transmembrane glycoprotein, is expressed on all leukocytes, platelets, and endothelial cells. It has been implicated in a variety of physiological and pathological activities through interacting with multiple partners, including cyclophilins, monocarboxylate transporters, Caveolin-1, and integrins. While CD147 is best known as a potent inducer of extracellular matrix metalloproteinases (hence also called EMMPRIN), it can also function as a key mediator of inflammatory and immune responses. Increased expression of CD147 has been implicated in the pathogenesis of a number of diseases, such as asthma-mediated lung inflammation, rheumatoid arthritis, multiple sclerosis, myocardial infarction and ischemic stroke. Therapeutic targeting of CD147 has yielded encouraging effects in a number of experimental models of human diseases, suggesting CD147 as an attractive target for treatment of inflammation-related diseases. Here we review the current understanding of CD147 expression and functions in inflammatory and immune responses and potential implications for treatment of inflammatory disorders.
Keywords: CD147, MMP, cyclophilin, MCT, integrin, inflammation, leukocyte, platelet.
Current Medicinal Chemistry
Title:CD147: A Novel Modulator of Inflammatory and Immune Disorders
Volume: 21 Issue: 19
Author(s): X. Zhu, Z. Song, S. Zhang, A. Nanda and G. Li
Affiliation:
Keywords: CD147, MMP, cyclophilin, MCT, integrin, inflammation, leukocyte, platelet.
Abstract: CD147, a transmembrane glycoprotein, is expressed on all leukocytes, platelets, and endothelial cells. It has been implicated in a variety of physiological and pathological activities through interacting with multiple partners, including cyclophilins, monocarboxylate transporters, Caveolin-1, and integrins. While CD147 is best known as a potent inducer of extracellular matrix metalloproteinases (hence also called EMMPRIN), it can also function as a key mediator of inflammatory and immune responses. Increased expression of CD147 has been implicated in the pathogenesis of a number of diseases, such as asthma-mediated lung inflammation, rheumatoid arthritis, multiple sclerosis, myocardial infarction and ischemic stroke. Therapeutic targeting of CD147 has yielded encouraging effects in a number of experimental models of human diseases, suggesting CD147 as an attractive target for treatment of inflammation-related diseases. Here we review the current understanding of CD147 expression and functions in inflammatory and immune responses and potential implications for treatment of inflammatory disorders.
Export Options
About this article
Cite this article as:
Zhu X., Song Z., Zhang S., Nanda A. and Li G., CD147: A Novel Modulator of Inflammatory and Immune Disorders, Current Medicinal Chemistry 2014; 21 (19) . https://dx.doi.org/10.2174/0929867321666131227163352
DOI https://dx.doi.org/10.2174/0929867321666131227163352 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biochemical Markers of Renal Function
Current Medicinal Chemistry Indoleamine 2,3-dioxygenase as a Modifier of Pathogenic Inflammation in Cancer and other Inflammation-Associated Diseases
Current Medicinal Chemistry Editorial: [Hot Topic: Chromogranin A at the Crossroads of Health and Disease]
Current Medicinal Chemistry Seasonal and Perennial Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Parasites in Rheumatoid Arthritis: Imminent Threat or Protective Effect?
Current Rheumatology Reviews Methotrexate: Should We Start Using it in Clinical Practice?
Current Drug Targets Knee Osteoarthritis and Exercise Adherence: A Review
Current Aging Science Receptor Guided 3D-QSAR Analysis of Thieno[2,3-b]Pyridine-5- Carbonitrile Inhibitors of Protein Kinase C Theta (PKC-θ )
Combinatorial Chemistry & High Throughput Screening Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment
Current Drug Targets Efficacy of the Newest COX-2 Selective Inhibitors in Rheumatic Disease
Current Pharmaceutical Design Immune Aging and Autoimmune Diseases in Children
Current Immunology Reviews (Discontinued) Selenoproteins and their Role in Oxidative Stress and Inflammation
Current Chemical Biology Animal Models of Lupus and Lupus Nephritis
Current Pharmaceutical Design Artemisinin, Promising Lead Natural Product for Various Drug Developments
Mini-Reviews in Medicinal Chemistry Antibody Recognition of Fluorinated Haptens and Antigens
Current Topics in Medicinal Chemistry Development of Colon Specific Microspheres of Flurbiprofen for Inflammatory Bowel Disease
Current Drug Delivery Targeting Thioredoxin Reductase: Anticancer Agents and Chemopreventive Compounds
Medicinal Chemistry Classical to Current Approach for Treatment of Psoriasis: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets The Metabolism and Disposition of Koumine, Gelsemine and Humantenmine from Gelsemium
Current Drug Metabolism Treating COPD in Older and Oldest Old Patients
Current Pharmaceutical Design